Establishment of pregnancy in the pig depends on downregulation of progesterone receptor (PGR) in the uterine luminal and glandular epithelium during the first week after breeding. The present study evaluated the regulation of endometrial PGR by progesterone and the possible role of endometrial tumor necrosis factor (ligand) superfamily member 11 (TNFSF11) and nuclear factor-kappa B (NFKB) activation in PGR expression. Mature, cycling gilts were inseminated (Day 0) and assigned to either untreated control (n ¼ 9) or one of two treatments that employed RU 486 to block progesterone action either before (treatment 1 [T1]) or after (treatment 2 [T2]) the initiation of PGR down-regulation. The T1 gilts were treated with RU 486 (400 mg/day) on Days 3-5 of pregnancy (n ¼ 9), and T2 gilts were treated with RU 486 on Days 6 and 7 of pregnancy (n ¼ 9). Uteri and ovaries were collected on Day 8 or 12 of gestation. The diameter of the conceptuses in T1 gilts was approximately half that in controls by Day 8, and normal conceptuses were not collected from any T1 gilts on Day 12. Endometrial PGR mRNA was more abundant in T1 and T2 gilts compared with control gilts. The PGR-B protein decreased from Day 8 to Day 12 in the luminal epithelium and, to some extent, in superficial glandular epithelium in control and T2 gilts. In T1 gilts, the PGR-B protein remained elevated (i.e., failed to undergo down-regulation) on Day 12. Blocking PGR action early in the cycle (i.e., on or before Day 5), therefore, prevented normal conceptus development, caused elevated PGR mRNA, and prevented the decrease in PGR protein that typically occurs in pigs. We could not confirm a role for NFKB activation in PGR down-regulation, because pigs with extreme differences in PGR and TNFSF11 expression (T1 and controls) had similar NFKB activation on Day 8. Activated NFKB within the luminal epithelium and glandular epithelium (both superficial and deep) was observed in T2 and control pigs on Day 12 when elongating conceptuses (presumably releasing interleukin 1 beta to activate NFKB) were recovered. Gilts treated with RU 486 had greater ovarian follicular growth and greater plasma estradiol concentrations. We conclude that the mechanisms controlling PGR down-regulation are progesteronedependent and occur between Day 3 and Day 6 of pregnancy. NFKB activation did not appear to have a role in PGR downregulation within the period that we studied. Blocking progesterone action after Day 6 did not reverse the process of PGR down-regulation, nor did it appear to affect the development of conceptuses collected on Day 12.
INTRODUCTION
Progesterone induces uterine quiescence, stimulates uterine histotroph secretion, and suppresses uterine immune responses during early pregnancy in mammals [1] [2] [3] . The actions of progesterone on tissue are controlled through interaction with the progesterone receptor (PGR), a prototypical steroid receptor with nuclear localization and activity. In the pig, the PGR mRNA and protein decrease in the uterine luminal epithelium during the first week of the estrous cycle and pregnancy [4, 5] . The decrease (i.e., down-regulation) in PGR is less pronounced in the uterine glandular epithelium and does not occur within the endometrial stroma or within the myometrium [4] . Uterine PGR downregulation occurs in a variety of mammalian species [6] . In the pig (Sus scrofa domestica), PGR down-regulation is associated with the loss of mucin 1 (MUC1) from the luminal epithelium, a process that may enable attachment of the conceptus to the uterine surface and establishment of pregnancy [7] .
Progesterone clearly plays a role in the temporal expression (occurring within the first week after ovulation) of PGR through its capacity to specifically down-regulate its own receptor. Cellular mechanisms that control the down-regulation itself, however, are largely unknown. Within the mouse mammary gland, progesterone induces the expression of tumor necrosis factor (ligand) superfamily member 11 (Tnfsf11; also known as Rankl) [8] , which activates nuclear factor-kappa B (NFKB), a pleiotrophic transcription factor complex. In humans, NFKB can regulate PGR expression by binding to a response element within the PGR gene [9] . Both TNFSF11 and TNFSF11 NFKB activator (TNFRSF11A, the receptor for TNFSF11, or RANK) are expressed within the uterus of the pig [5] and, theoretically, could be involved in a paracrine mechanism through which progesterone induces the expression of TNFSF11 to activate NFKB and down-regulate PGR expression.
To test this hypothesis, RU 486, a traditional progesterone antagonist, was used to block progesterone action during two periods of early pregnancy in the pig (before and after initiation of PGR down-regulation). The temporal and spatial PGR expression, TNFSF11 expression, NFKB activation, and related endpoints on Days 8 and 12 of pregnancy were analyzed.
MATERIALS AND METHODS

Experimental Design, Blood Collection, and Tissue Collection
The procedures used in the present study were approved by the University of Missouri-Columbia Institutional Animal Care and Use Committee. Twenty-seven cycling Large White-Landrace crossbred gilts were observed for estrous behavior twice daily. Gilts were artificially inseminated at the onset of estrus (Day 0) and 1 day later with fresh semen collected from a single Large WhiteLandrace crossbred boar. Inseminated gilts were assigned randomly to one of three treatments and one of two slaughter days (3 3 2 factorial design). The treatment groups were as follows: treatment 1 (T1), 400 mg i.m. of RU 486 (Roussel-UCLAF) on Days 3-5 (n ¼ 5 slaughtered on Day 8 and n ¼ 4 slaughtered on Day 12); treatment 2 (T2), 400 mg i.m. of RU 486 on Days 6 and 7 (n ¼ 4 slaughtered on Day 8 and n ¼ 5 slaughtered on Day 12); and untreated control (control; n ¼ 5 slaughtered on Day 8 and n ¼ 4 slaughtered on Day 12). The RU 486 was mixed with sterile corn oil to a concentration of 100 mg/ml and administered i.m. into the neck (4 ml/day). Blood samples (10 ml) were collected from the jugular vein using vacutainer tubes containing 100 ll of a 15% solution of potassium ethylenediaminetetra-acetic acid (EDTA; Tyco Healthcare Group). The blood was centrifuged at 1500 3 g for 15 min, and plasma was decanted and stored at À208C until radioimmunoassay (RIA).
Gilts were euthanized with Euthasol (Virbac AH) on Day 8 or 12 of pregnancy. The abdomen was opened, and the reproductive tract was removed, placed in a plastic bag, and immersed in ice. Upon arrival to the laboratory (within 5 min), the ovaries were removed and weighed, the number of corpora lutea (CL) counted, and the diameter of ovarian follicles visible on the surface measured. The uterus was then weighed, and the broad ligament was dissected free of the uterine horns. The uterus was washed with ice-cold saline and placed on an ice-cold dissection tray. Cross-sectional pieces of the uterine horn near the uterine bifurcation were removed and fixed by placing them in 10% buffered formalin phosphate (Fisher Scientific). After 48 h, the pieces were imbedded in paraffin blocks by the University of Missouri Veterinary Diagnostic Laboratory. Conceptuses were recovered from uterine horns by flushing twice with 20 ml of PBS. The contents of the flush (including conceptuses) were examined under a light microscope. The morphology was assessed, and the diameter of each conceptus on Day 8 was measured using a calibrated eyepiece micrometer. Conceptuses collected on Day 8 were considered to be normal if hatched from the zona pellucida. On Day 12, spherical, ovoid, tubular, and elongated conceptuses were considered to be normal. After the flush, one uterine horn was cut along its antimesometrial border, and 5-10 g of endometrium were dissected from the uterus, snap-frozen in liquid nitrogen, and stored at À808C.
RNA Isolation, Reverse Transcription, and Real-Time RT-PCR
The sample of endometrium (5-10 g) was ground under liquid nitrogen. A 100-mg sample of the ground powder was used for total cellular RNA isolation with 1 ml of TRIzol reagent (Invitrogen) following the manufacturer's recommendations. The integrity of RNA was determined by calculating the ratio of absorbance at 260 nm and 280 nm (NanoDrop ND-1000; NanoDrop Technologies), followed by gel electrophoresis (0.8% agarose gel in 0.09 M Tris-borate and 0.002 M EDTA buffer with 0.5 lg/ml of ethidium bromide). The RNA was stored at À808C before reverse transcription of 5 lg of total cellular RNA to cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Primer sets for PGR-B (amplifies cDNA derived from PGR-B mRNA, only), PGR-AB (amplifies cDNA for both PGR-A and PGR-B mRNA), TNFSF11, TNFRSF11A, prostaglandin-endoperoxide synthase 2 (PTGS2), fibroblast growth factor 7 (FGF7), and beta actin (ACTB) were designed based on porcine nucleotide sequences ( Table 1 ). The PCR products produced from primer sets were DNA sequenced at the University of Missouri DNA Core to verify amplification of the target sequence. The real-time RT-PCR was prepared with 1 lM concentrations of both forward and reverse primers and 1 ll (100 ng RNA equivalent) of the cDNA sample using Power SYBR Green (Applied Biosystems). One plate per primer set was used, and all samples were run in triplicate on a single plate. Within each plate, high, medium, and low control samples (sequential 1:4 dilutions) of pooled cDNA were run in triplicate and used as a standard. Each PCR 96-well plate contained a ''no-template control'' (water substituted for cDNA in the reaction) to ensure that no amplification occurred in samples without cDNA. The PCR reactions were performed and SYBR green fluorescence quantified using the ABI Prism 7500 Sequence Detector (Applied Biosystems). Thermocycler settings consisted of an initial temperature of 508C for 2 min and a polymerase activation temperature of 958C for 10 min, followed by 40 PCR cycles consisting of two stages, melting at 958C for 15 sec and annealing and extension at 608C for 1 min. Analysis of amplification plots was performed by the Sequence Detection Software (Applied Biosystems).
Data from the serial dilutions of the control sample were used to calculate the amplification efficiencies for the seven real-time RT-PCR targets. The equation used for the efficiency calculation was efficiency ¼ 10 (À1/slope) . The slope refers to the slope of a linear plot of C T values achieved by the high, medium, and low pooled cDNA standards versus the log of the dilution. Foldchange differences for the respective samples were calculated using the equation fold-change ¼ efficiency ðmean medium control CTÀmean sample C T Þ , where the medium control was the same sample in each plate (i.e., an internal control standard for between-plate normalization).
Immunohistochemistry for PGR-B
Tissue sections (thickness, 5 lm) were deparaffinized and rehydrated for immunohistochemistry (IHC). As an epitope retrieval technique, slides were boiled for 6 min in 0.01 M sodium citrate buffer. Sections were cooled for 45 min, incubated in 0.3% H 2 O 2 for 30 min to block endogenous peroxidase activity, and then submersed in PBS for 5 min. Following PBS submersion, a normal (nonimmune) blocking serum (VECTASTAIN Elite ABC kit PK-6101; Vector Laboratories, Inc.) was applied for 20 min and then blotted off the slides. A primary monoclonal rabbit anti-PGR antibody (C1A2; Cell Signaling Technology, Inc.) was diluted in PBS (1:200), and 250 ll of solution were then added to each slide. Slides were allowed to incubate with the primary antibody overnight at room temperature. The next day, a biotinylated secondary antibody (VECTAS-TAIN Elite ABC kit) was added to each slide according to the manufacturer's recommendations. Following incubation with the ABC kit reagents, tissue sections were incubated with the ImmPACT DAB peroxidase substrate (SK-4105; Vector Laboratories) for 5 min. Afterward, sections were gently rinsed in water and counter-stained with hematoxylin and Scott Bluing Reagent (Statlab Medical Products, Inc.). A negative-control slide was made using preimmune rabbit immunoglobulin (Ig) G in place of the primary antibody.
Two sections per pig were scored for PGR-B protein within nuclei of the luminal epithelium, glandular epithelium near the lumen (surface glandular epithelium), glandular epithelium distal to the lumen (deep glandular epithelium), myometrium, and stromal cells by two independent persons using a Leica light microscope at 4003 magnification. Each cell type was scored on a scale of 0-4, where 0 indicates 0% of nuclei and 4 indicates 100% of nuclei stained positive for PGR protein.
IHC for NFKB
Uterine tissue sections (thickness, 5 lm) were mounted onto frosted white microscope slides, deparaffinized, and rehydrated for IHC. Epitope retrieval was achieved by boiling slides for 6 min in 0.01 M sodium citrate buffer. Slides were allowed to cool for 45 min, followed by incubation at room temperature overnight with 500 ll of a rabbit polyclonal antibody diluted in PAT (0.001% Tween-20 and 0.001% sodium azide in 1.0% PBS) solution to 2 lg/ml. The antibody was directed against RELA, the p65 subunit of NFKB (sc-372; Santa Cruz Biotechnology). Following overnight incubation, slides were placed in PBS for 30 min before adding 500 ll of a secondary donkey anti-rabbit monoclonal antibody, containing a Cy2 conjugate (711-225-152; Jackson ImmunoResearch Laboratories), in PAT solution (15 lg/ml). Slides were allowed to incubate at room temperature with the secondary antibody for 70 min before being resubmerged in PBS. The secondary antibody/PAT solution was incubated with a washed bovine liver powder for 1 h at 378C to reduce background fluorescence. Cover slips were then mounted over the uterine tissue with Flouromount-G (SouthernBiotech), and the slides were then refrigerated at 4-88C overnight in the dark. A negative-control slide was made using preimmune rabbit IgG in place of the primary antibody.
Nuclear factor-kappa B activation in the uterus was scored by three independent persons using a Leica light microscope with a green fluorescent protein filter at 4003 magnification. Two tissue sections per pig were scored for NFKB activation (nuclear localization) in the luminal epithelium, surface glandular epithelium, and deep glandular epithelium on a scale of 0-10, where 0 indicates no nuclear localization and 10 indicates complete nuclear localization.
Radioimmunoassays
Plasma progesterone concentrations were measured using a Coat-A-Count RIA kit (Siemens Medical Solutions Diagnostics). A dilution series and added mass assay were performed to verify linearity and recovery. The intra-and interassay coefficients of variation (CVs) were 6.0% and 16.8%, respectively. The assay sensitivity was 0.02 ng/ml. The cross-reactivity of RU 486 in the progesterone assay was 0.0005%. Plasma estradiol concentrations were measured using an RIA protocol previously described for the bovine [10] and validated for the pig [11] . The intra-and interassay CVs were 2.3% and 14.0%, respectively. The assay sensitivity was 0.25 pg/ml.
Statistical Analysis
The present study was conducted using a completely randomized design with two factors (treatment and day of pregnancy). Uterine and ovarian UTERINE PROGESTERONE RECEPTOR measurements, fold-change for expression of the respective genes, IHC score for NFKB activation, and IHC score for staining of PGR-B were analyzed using the general linear models procedure of the Statistical Analysis System (SAS; SAS Institute, Inc.). The model included the effects treatment, day, and the treatment 3 day interaction. Preplanned orthogonal contrasts were performed (contrast 1 [C1], control vs. RU 486-treated [T1 and T2] gilts; contrast 2 [C2], T1 vs. T2 gilts). Least squares means (lsmeans) and standard errors of the lsmeans were generated using the lsmeans statement of SAS.
When heterogeneous variance was encountered, a log 10 transformation was employed to reduce the heterogeneity.
Plasma progesterone and estradiol concentrations were repeated measures and were analyzed using the PROC MIXED procedure in the SAS. The model statement included treatment, day, and the treatment 3 day interaction. Pig nested within treatment was included as a random effect, and day was defined as a repeated effect. Analyses of plasma estradiol and progesterone concentration between Day 2 and Day 7 included all gilts. Analyses between Day 8 and Day 11 included only those gilts that were euthanized on Day 12 (those euthanized on Day 8 of pregnancy were already deceased at that time).
The percentage of gilts with normal conceptus development was analyzed using a chi-square test. Correlation coefficients and equations for linear regressions were determined using the PROC REG procedure in the SAS. Regardless of the statistical test applied, significance was declared at P , 0.05 unless stated otherwise.
RESULTS
Plasma Steroid Concentrations
Plasma progesterone concentrations increased from Day 2 to Day 11 (Fig. 1A) . Before Day 7, an effect of day (P , 0.001) was observed, but no effect of treatment on plasma progesterone was found (Fig. 1A) . From Day 8 to Day 11, an effect of day (P , 0.001) was noted, and a tendency existed for a treatment 3 day interaction (P ¼ 0.064). Gilts treated with RU 486 tended to have greater plasma progesterone concentrations compared with control gilts on Day 9 (T1 gilts) or on Days 10 and 11 (T2 gilts).
Plasma estradiol concentrations remained relatively unchanged in control gilts but increased approximately 1-2 days after RU 486 treatment in both T1 and T2 gilts (Fig. 1B) . The T1 gilts had greater plasma estradiol concentrations than control and T2 gilts from Day 2 to Day 7 (treatment 3 day, P , 0.001). Both T1 and T2 gilts had greater plasma estradiol concentrations than control gilts from Day 8 to Day 11 (treatment 3 day, P , 0.05).
Gross Morphology of the Uterus and Ovaries
Uterine weight was affected by day (P , 0.01) and treatment (P , 0.05) ( Table 2 ). The weight of the uterus was greater on Day 12 (800 6 37 g) when compared with Day 8 (650 6 39 g). Uterine weight for T1 gilts was less than for T2 and control gilts (785 6 44, 608 6 46, and 781 6 49 g for control, T1, and T2, respectively; Day 8 and Day 12 combined; P , 0.05).
Gilts treated with RU 486 had heavier ovaries than controls (16.1 6 1.0, 17.9 6 1.0, and 19.8 6 1.1 g for control, T1, and T2, respectively; C1, P , 0.05). A tendency was observed for TABLE 1. GenBank accession number, gene name, oligonucleotide primer sequence, location of the primer within the GenBank sequence, length of the amplicon, and amplification efficiency for the individual genes whose expression was measured by real-time reverse transcription polymerase chain reaction (RT-PCR).
GenBank
Gene UTERINE PROGESTERONE RECEPTOR a treatment 3 day interaction (P ¼ 0.087), because ovarian weight tended to be greater in T1 (19.1 6 1.5 g) and T2 (22.5 6 1.5 g) gilts compared with controls (15.3 6 1.3 g) on Day 12 of pregnancy. Greater ovarian weight in RU 486-treated gilts was associated with greater ovarian follicular growth and with the presence of newly formed CL on the ovary (Fig. 2) . Gilts treated with RU 486 had greater mean follicular diameters compared with control gilts (3.6 6 0.5, 5.6 6 0.5, and 4.9 6 0.5 mm for control, T1, and T2, respectively; Day 8
and Day 12 combined; C1, P , 0.05) ( Table 2) . A tendency was noted for an effect of treatment on the number of CL, because gilts treated with RU 486 tended to have more CL than control gilts (13.7 6 1.0 16.8 6 1.0, and 15.0 6 1.0 and for control, T1, and T2, respectively; Day 8 and Day 12 combined; P ¼ 0.072).
Development of Conceptuses
The percentage of gilts with normal conceptus development was least in T1 gilts (chi-square ¼ 7.00, P , 0.05) ( Table 3 ). On Day 8 of pregnancy, all the control and T2 gilts had pregnancies with conceptuses that appeared developmentally normal (hatched blastocysts), whereas 60% of the T1 gilts had pregnancies with normal conceptuses. Although three of five T1 gilts produced morphologically normal conceptuses on Day 8 (hatched blastocysts), the conceptus diameters tended to be less (P , 0.10) than for control or T2 gilts (0.6 6 0.1, 0.3 6 0.1, 0.5 6 0.1 mm for control, T1, and T2, respectively).
On Day 12, conceptuses collected from T2 and control gilts were either elongated or spherical (Table 3 ). T1 gilts did not have recoverable conceptuses on Day 12. Unfertilized oocytes were recovered from three T1 gilts on Day 12.
Endometrial PGR mRNA Expression and Protein
The amount (relative fold-difference from internal standard) of endometrial PGR-B mRNA was greater in T1 gilts (9.1 6 1.0) compared with control (3.2 6 1.0) and T2 (5.9 6 1.0) gilts (effect of treatment, P , 0.01; Day 8 and Day 12 combined) ( Table 4) . Treatment also affected expression of the PGR-AB (primer pair positioned so that both PGR-A and PGR-B are amplified; 10.7 6 1.1, 7.0 6 1.0, and 3.5 6 1.0 for T1, T2, and control, respectively; P , 0.001). A high correlation was found between the data for PGR-B and PGR-AB (PGR-B ¼ 0.92 Á PGR-AB -0.27; r 2 ¼ 0.84, P , 0.001). A treatment 3 day interaction was found (P , 0.001) for PGR-B protein score within the luminal epithelium (Figs. 3A  and 4) . PGR-B protein in the luminal epithelium of control and T2 gilts decreased from Day 8 to Day 12. In the T1 gilts, PGR-B protein remained elevated on Day 12. Within the surface glandular epithelium, a treatment 3 day interaction was noted (P , 0.01) for PGR-B protein (Fig. 3B) . The PGR-B protein was similar for control, T1, and T2 gilts on Day 8. The PGR-B protein decreased from Day 8 to Day 12 in control and T2 gilts. The PGR-B protein remained elevated in T1 gilts on Day 12. No effect of treatment or day was observed for PGR-B protein within the deep glandular epithelium (Fig. 3C) .
A tendency for an effect of treatment was observed (treatment, P ¼ 0.06; C1, P , 0.06; Day 8 and Day 12 combined) for PGR-B in the stroma, because the PGR-B protein in control gilts (1.9 6 0.3) tended to be less than in T1 (2.3 6 0.3) and T2 (2.9 6 0.3) gilts. A similar response was observed within the myometrium (effect of treatment, P , 0.001; C1, P , 0.001; Day 8 and Day 12 combined). The PGR-B protein in myometrium of control gilts (3.1 6 0.1) was less than in T1 (3.7 6 0.1) and T2 (3.9 6 0.1) gilts.
Endometrial TNFSF11 and TNFRSF11A mRNA Expression
The data for TNFSF11 were log 10 transformed to eliminate heterogeneous variance. An effect of treatment on TNFSF11 mRNA expression within the endometrium was found (P , 0.005; Day 8 and Day 12 combined), as was a tendency for an effect of day (P ¼ 0.098) ( Table 4 ). The TNFSF11 expression was greater in RU 486-treated gilts (C1, P , 0.01), and T1 134 gilts had greater expression than T2 gilts (C2, P , 0.05). No effect of treatment or day was found on endometrial expression of TNFRSF11A (the receptor for TNFSF11).
Endometrial PTGS2, FGF7, and ACTB mRNA Expression Endometrial expression of ACTB (control housekeeping gene) was not affected by treatment or day. A treatment 3 day interaction was observed for endometrial PTGS2 mRNA expression (P , 0.01). The PTGS2 mRNA expression was greater in control and T2 gilts when compared with T1 gilts on Day 12. An effect of day was found (P , 0.05) on endometrial FGF7 mRNA expression. The data for FGF7 were log 10 transformed to eliminate heterogeneous variance. A treatment 3 day interaction was noted for endometrial FGF7 expression (P , 0.001), because FGF7 expression was greater in control and T2 gilts compared with T1 gilts on Day 12.
Uterine NFKB Activation
An effect of day was observed (P , 0.01) on NFKB activation within the luminal epithelium (Figs. 5A and 6 ). NFKB activation in the luminal epithelium increased from Day 8 (2.4 6 0.3) to Day 12 (3.8 6 0.4). On Day 12 and within luminal epithelium, the NFKB activation score was greater (P , 0.05) for control gilts, and tended to be greater (P ¼ 0.093) for T2 gilts, compared with T1 gilts. The activation of NFKB was observed near the conceptus and not distal to the conceptus (Fig. 7) . Within the surface glandular epithelium and the deep glandular epithelium, an effect of day on NFKB activation was observed (P ¼ 0.082 and P , 0.05 for surface and deep glandular epithelium, respectively) (Fig. 5, B and C) . In both tissue types, NFKB activation tended to increase from Day 8 to Day 12 (from 1.5 6 0.2 to 2.0 6 0.2 for surface glandular epithelium and from 1.4 6 0.2 to 1.9 6 0.2 for deep glandular epithelium).
DISCUSSION
The increase in progesterone after ovulation is associated with a down-regulation of the PGR in the uterine epithelium in a number of mammalian species [6] . PGR down-regulation in the pig uterus is initiated by Day 8 and is completed by Day 12 in both cyclic and pregnant animals [4, 12, 13] . During pregnancy, PGR down-regulation is thought to enable conceptus attachment to the uterine surface and establishment of pregnancy through a mechanism involving the loss of MUC1 [7] . How progesterone causes down-regulation of its own receptor is not clearly understood. We hypothesized that PGR down-regulation is caused by progesterone-induced uterine epithelial expression of TNFSF11, acting in an autocrine fashion to activate NFKB within the luminal epithelium and glandular epithelium. NFKB may then enter the nucleus, bind a response element upstream of the PGR gene, and block PGR expression, resulting in PGR downregulation within the luminal epithelium and glandular epithelium. Gilts were treated with RU 486, a PGR antagonist, to test the hypothesis that progesterone induces TNFSF11 expression within the luminal epithelium and glandular epithelium, resulting in activation of NFKB and PGR downregulation. Because RU 486 has the capacity to bind the glucorticoid receptor, glucorticoid action within the uterus may have been reduced as well. RU 486 was administered to gilts on Days 3-5 to block PGR down-regulation before it begins (T1) or on Days 6 and 7 to block PGR down-regulation following initiation of receptor loss (T2). Gilts were then euthanized on Days 8 and 12 of pregnancy to measure endometrial PGR, TNFSF11, and TNFRSF11A mRNA and NFKB activation. The present study was not conducted to assess the effects on ovarian physiology; nonetheless, the effects of RU 486 on the ovary were noted.
Blocking progesterone action during early pregnancy could have consequences for developing conceptuses, and indeed, this was observed (Table 3 ). The diameter of the conceptus in T1 gilts was approximately half that in control gilts by Day 8. Normal pregnancies were not observed on Day 12 in T1 gilts. Vallet and Christenson [14] reported a 50% reduction in conceptus diameter on Day 11 when gilts were treated with RU 486 on Day 2 of pregnancy. Blocking progesterone action shortly after insemination beginning either on Day 2 [14] or Day 3 (present study), therefore, was incompatible with conceptus survival through Day 12. Treating gilts with RU 486 on Day 6 and Day 7 (T2) slightly reduced the diameter of the conceptuses by Day 8; nonetheless, the majority of T2 gilts had elongated conceptuses on Day 12. Progesterone action during the first 6 days of pregnancy may be adequate to support gestation through Day 12, because there appeared to be only a small effect of RU 486 when it was administered on Days 6 and 7.
We measured PGR mRNA in the whole endometrium on both Day 8 and Day 12. To do this, we designed an ''upstream'' primer pair that would only amplify PGR-B, the longer of the two PGR mRNAs. We also designed a ''downstream'' primer pair (PGR-AB) that measured PGR-A (the shorter of the two PGR mRNAs) plus PGR-B. The PGR-A mRNA transcript is a shortened form of PGR mRNA generated by a downstream transcription start site. Its sequence is entirely found within PGR-B; thus, it is impossible to measure PGR-A mRNA alone using a real-time RT-PCR assay. The data for PGR-B and PGR-AB mRNA were highly correlated. This implies that either the bulk of the transcripts are PGR-B or that PGR-B and PGR-A are transcriptionally regulated in a similar manner. Control gilts had relatively low PGR mRNA on both Day 8 and Day 12, suggesting that the PGR down-regulation in control gilts had already occurred by Day 8 (Table 4) . This would agree with the findings of Ross et al. [5] , who showed that uterine epithelial PGR mRNA continued to decrease after estrus (Day 0) and was substantially reduced by Day 7.5 in pigs. Blocking progesterone action with RU 486 on Days 3-5 (T1) or on Days 6 and 7 (T2) increased endometrial PGR mRNA (Table 4) . These results support the general concept that progesterone itself causes down-regulation of PGR transcription, because blocking the PGR with RU 486 increased the amount of mRNA. Treatment of gilts early after insemination (T1) led to greater PGR mRNA expression when compared with control or T2 gilts on Day 8. This difference was less pronounced on Day 12. RU 486 and its metabolites are capable of antagonizing progesterone action for 6-7 days. Regardless of RU 486 treatment (T1 and T2), gilts were probably under the influence of RU 486 when they were euthanized (Day 8 or 12). Small relative differences in the amount of absolute mRNA within the RU 486 groups may reflect the circulating RU 486 activity on the respective days of euthanization.
The two PGR mRNAs give rise to the two PGR proteins (PGR-A and PGR-B) that differ in their N-termini. PGR-B is 136 the longer of the two forms. We used IHC to specifically measure PGR-B protein. We also measured PGR-AB using two separate antibodies directed against a region found in both PGR-A and PGR-B but found that both antibodies stained the cytoplasm in addition to the nucleus (data not shown). These results suggest that the PGR-AB antibodies were perhaps detecting degraded PGR within the cytoplasm. For this reason, we opted for the PGR-B antibody that was specific for one protein (PGR-B) and provided nuclear localization. The PGR-B protein decreased from Day 8 to Day 12 in the luminal epithelium and, to some extent, in the superficial glandular epithelium in control and T2 gilts. In T1 gilts that were treated with RU 486 on Days 3-5, PGR-B remained elevated on Day 12. In other words, the PGR-B failed to decrease in a normal pattern. Blocking PGR action early in the cycle (i.e., on or before Day 5), therefore, caused elevated PGR mRNA (Table  4 ) and prevented the decrease in PGR protein that typically occurs in pigs (Fig. 4) . Treating gilts on Day 6 (T2) increased PGR mRNA as well, but the decrease in PGR protein on Day 12 clearly occurred. The mechanisms that lead to the decrease in PGR protein before Day 12, therefore, are dependent on progesterone acting via the PGR and are already irreversible by the end of Day 5.
The present study is not the first to functionally demonstrate a progesterone-dependent decrease in PGR in the pig. Indeed, Ka et al. [15] demonstrated in ovariectomized pigs that a PGR antagonist could block PGR down-regulation in the luminal epithelium. The loss of PGR-B protein within the luminal epithelium and surface glandular epithelium was not observed in the deep glandular epithelium. This observation is consistent with previous studies of the PGR, in which the amount of PGR down-regulation was greatest in the luminal epithelium and surface glandular epithelium [4] . In general, we did observe more PGR protein in stroma and myometrium of RU 486-treated gilts compared with controls. It is well accepted that these tissue layers express PGR and that its regulation is entirely different from that found in luminal epithelium and glandular epithelium. Blocking progesterone action in these tissues increased PGR protein. Within these tissues, therefore, progesterone may have some capacity to control its own receptor expression.
Nuclear factor-kappa B may regulate the actions of PGR in some tissues [9, 16] if it can be activated by a progesteronemediated increase in TNFSF11 expression [8] . For this to occur, progesterone induces TNFSF11 expression, TNFSF11 activates NFKB, and NFKB binds the PGR gene, regulating PGR expression [9] . The amount of NFKB activation was low on Day 8 and was similar for treated (T1 and T2) and control gilts. At the same time, TNFSF11 expression was increased by RU 486, particularly in gilts treated with RU 486 on Days 3-5 Negative-control slides were made using preimmune rabbit IgG in place of the primary antibody. Images were taken with a Leica light microscope using a green fluorescent protein (GFP) filter. GE, glandular epithelium; LE, luminal epithelium; ST, stroma. Bar ¼ 50 lm.
(T1). These same gilts (T1) had the greatest amount of PGR-B mRNA on Day 8 (Table 4) . Greater TNFSF11 expression on Day 8, therefore, was not associated with NFKB activation, nor was it associated with a decrease in PGR mRNA. Collectively, the results would argue against a role for TNFSF11 in NFKB activation and PGR down-regulation in the luminal epithelium. The progesterone-driven TNFSF11 expression reported within the mammary gland of the mouse may be a tissue-or species-specific event that is absent from the pig uterus. We could not exclude the possibility that NFKB initiates the process of PGR down-regulation before Day 8, because the PGR mRNA appeared to have already undergone this event in control gilts by that time. We can perhaps conclude that NFKB activation is not responsible for maintaining a low amount of PGR mRNA, because pigs with extreme differences in PGR mRNA (T1 and control) had similar NFKB activation on Day 8.
We did observe activated NFKB within endometrium of control and T2 gilts on Day 12 (Figs. 5 and 6 ). This activation was found within luminal epithelium but was also observed, to some extent, within both superficial and deep glandular epithelium. Release of interleukin 1 beta (IL1B) from the elongating conceptuses on Day 12 would be a strong candidate for the NFKB activation that we observed. The pig conceptus increases gene expression for IL1B on Day 11 of gestation [17] , and we have shown that an intrauterine infusion of IL1B causes NFKB activation (White and Geisert, unpublished observation). The activation of NFKB on Day 12 was found in control and T2 gilts but not in T1 gilts, apparently because conceptuses of T1 gilts did not survive to Day 12 ( Table 3 ). Activation of NFKB by the porcine conceptus appears to be a paracrine event within the uterine epithelium, where activation clearly occurs within luminal epithelial cells near the conceptus but is absent within luminal epithelial cells distal to the conceptus (Fig. 7) . Endometrial PTGS2 is a gene for which expression is known to be induced by NFKB activation [18] . The expression of PTGS2 was approximately 2-and 3-fold greater in control and T2 gilts, respectively, compared with T1 gilts on Day 12. Likewise, FGF7, a uterine pregnancy marker produced in response to progesterone and conceptus estradiol [15] , was increased in control and T2 gilts on Day 12. Blocking progesterone action with RU 486 after Day 6 of pregnancy (T2) did not appear to be detrimental to conceptus elongation, activation of NFKB, or release of either IL1B or estradiol from the developing conceptuses.
In addition to the molecular responses within the uterus (described above), we noted general effects of RU 486 on the uterus itself, on blood steroid concentrations, and on ovarian morphology. The T1 gilts had lighter uteri on both Day 8 and Day 12, perhaps reflecting a function for progesterone in maintaining uterine weight early in the pregnancy. An effect of RU 486 was also noted on plasma progesterone concentrations. Progesterone concentrations were increased from Day 8 to Day 11 of pregnancy in RU 486-treated gilts compared with controls. The increase in plasma progesterone concentrations appeared to be greatest in the T2 gilts (Fig. 1A) . RU 486 may block the negative feedback of progesterone on gonadotropinreleasing hormone release from the hypothalamus and, hence, increase luteinizing hormone (LH) secretion from the anterior pituitary. This mechanism was demonstrated by Forcelledo et al. [19] , who reported greater LH and progesterone in RU 486-treated rats. Gilts treated with RU 486 also had larger follicles and a large increase in plasma estradiol following treatment (Fig. 1B) . The removal of the hypothalamic negative feedback by RU 486 could theoretically explain greater follicular development and estradiol secretion as well. The sharp decline in plasma estradiol concentrations that occurred between Day 10 and Day 11 in T1 gilts was suggestive of ovulation. Indeed, accessory CL were detected among mature CL in the present study (Fig. 2) , and we flushed unfertilized oocytes from the uterine horns of three of five T1 gilts on Day 12. That the RU 486-treated gilts ovulated during this experiment confirms the treatment we applied was systemically active, in that progesterone typically blocks ovulation.
In addition to a systemic effect, progesterone may have a local effect on the ovary, influencing follicular recruitment. Flowers et al. [20] demonstrated that preovulatory follicular growth and estradiol secretion initially occurs in response to the decrease in progesterone and independent of LH and FSH. Declining progesterone, therefore, may remove a direct negative effect that progesterone has on the ovary. By treating gilts with RU 486, we may have removed this direct negative effect of progesterone on the ovary and initiated a preovulatory wave of follicular development.
In conclusion, administering RU 486 beginning on Day 3 of pregnancy prevented PGR down-regulation and blocked conceptus development. Administering RU 486 beginning on Day 6 had little effect on PGR down-regulation or development of the conceptus. The mechanisms controlling PGR downregulation, therefore, are progesterone-dependent and occur between Days 3 and 6 of pregnancy. We did not find an association between uterine TNFSF11 expression, NFKB activation, and PGR down-regulation on Days 8 and 12 of pregnancy. 
